PLoS ONE (Feb 2008)

Striatal proteomic analysis suggests that first L-dopa dose equates to chronic exposure.

  • Birger Scholz,
  • Marcus Svensson,
  • Henrik Alm,
  • Karl Sköld,
  • Maria Fälth,
  • Kim Kultima,
  • Céline Guigoni,
  • Evelyne Doudnikoff,
  • Qin Li,
  • Alan R Crossman,
  • Erwan Bezard,
  • Per E Andrén

DOI
https://doi.org/10.1371/journal.pone.0001589
Journal volume & issue
Vol. 3, no. 2
p. e1589

Abstract

Read online

L-3,4-dihydroxypheylalanine (L-dopa)-induced dyskinesia represent a debilitating complication of therapy for Parkinson's disease (PD) that result from a progressive sensitization through repeated L-dopa exposures. The MPTP macaque model was used to study the proteome in dopamine-depleted striatum with and without subsequent acute and chronic L-dopa treatment using two-dimensional difference in-gel electrophoresis (2D-DIGE) and mass spectrometry. The present data suggest that the dopamine-depleted striatum is so sensitive to de novo L-dopa treatment that the first ever administration alone would be able (i) to induce rapid post-translational modification-based proteomic changes that are specific to this first exposure and (ii), possibly, lead to irreversible protein level changes that would be not further modified by chronic L-dopa treatment. The apparent equivalence between first and chronic L-dopa administration suggests that priming would be the direct consequence of dopamine loss, the first L-dopa administrations only exacerbating the sensitization process but not inducing it.